Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | GPR3 | P46089 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18566674 | 0.85 | GPR3 (0.58) | HTTMAPTGPR3HSD17B10KDM4E | |
| SCHEMBL383526 | 0.82 | NTRK1 (0.48) | HTTMAPTATMKDM1ANTRK1 | |
| SCHEMBL14802158 | 0.81 | MAPT (0.68) | HTTMAPTGPR3ATMCYP2C19 | |
| SCHEMBL10977307 | 0.79 | HTT (0.66) | HTTMAPTGPR3ATMCYP2C19 | |
| SCHEMBL10167907 | 0.79 | HTT (0.66) | HTTMAPTGPR3ATMCYP2C19 | |
| SCHEMBL9352178 | 0.79 | HTT (1.00) | HTTMAPTGPR3ATMCYP2C19 | |
| SCHEMBL29466066 | 0.79 | GPR3 (0.71) | HTTMAPTGPR3ATMCYP2C19 | |
| SCHEMBL21312375 | 0.79 | GPR3 (0.71) | HTTMAPTGPR3ATMCYP2C19 | |
| SCHEMBL21975440 | 0.79 | GPR3 (0.44) | HTTMAPTGPR3ALDH1A1NQO2 | |
| SCHEMBL53107 | 0.79 | GPR3 (0.71) | HTTMAPTGPR3ATMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330456-B8 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| US-7115619-B2 | N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330456-A2 | N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | TERT, MKI67, NQO2 | HTT 1530/4885MAPT 2342/4885GPR3 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.